1. Home
  2. CRVS vs CIX Comparison

CRVS vs CIX Comparison

Compare CRVS & CIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRVS
  • CIX
  • Stock Information
  • Founded
  • CRVS 2014
  • CIX 1993
  • Country
  • CRVS United States
  • CIX United States
  • Employees
  • CRVS N/A
  • CIX N/A
  • Industry
  • CRVS Biotechnology: Pharmaceutical Preparations
  • CIX Industrial Machinery/Components
  • Sector
  • CRVS Health Care
  • CIX Consumer Discretionary
  • Exchange
  • CRVS Nasdaq
  • CIX Nasdaq
  • Market Cap
  • CRVS 451.0M
  • CIX 411.4M
  • IPO Year
  • CRVS 2016
  • CIX 1998
  • Fundamental
  • Price
  • CRVS $8.94
  • CIX $28.20
  • Analyst Decision
  • CRVS Buy
  • CIX
  • Analyst Count
  • CRVS 4
  • CIX 0
  • Target Price
  • CRVS $12.83
  • CIX N/A
  • AVG Volume (30 Days)
  • CRVS 1.0M
  • CIX 9.8K
  • Earning Date
  • CRVS 11-12-2024
  • CIX 11-06-2024
  • Dividend Yield
  • CRVS N/A
  • CIX 4.11%
  • EPS Growth
  • CRVS N/A
  • CIX N/A
  • EPS
  • CRVS N/A
  • CIX 1.52
  • Revenue
  • CRVS N/A
  • CIX $150,690,000.00
  • Revenue This Year
  • CRVS N/A
  • CIX N/A
  • Revenue Next Year
  • CRVS N/A
  • CIX N/A
  • P/E Ratio
  • CRVS N/A
  • CIX $18.36
  • Revenue Growth
  • CRVS N/A
  • CIX N/A
  • 52 Week Low
  • CRVS $1.30
  • CIX $20.48
  • 52 Week High
  • CRVS $10.00
  • CIX $39.91
  • Technical
  • Relative Strength Index (RSI)
  • CRVS 60.34
  • CIX 45.87
  • Support Level
  • CRVS $8.02
  • CIX $27.50
  • Resistance Level
  • CRVS $8.71
  • CIX $31.14
  • Average True Range (ATR)
  • CRVS 0.86
  • CIX 1.47
  • MACD
  • CRVS -0.17
  • CIX -0.17
  • Stochastic Oscillator
  • CRVS 52.25
  • CIX 11.86

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

About CIX CompX International Inc.

Compx International Inc is a manufacturer of security products. Its security products are used in recreational transportation, postal, office & institutional furniture, cabinetry, tool storage, healthcare, and a variety of other industries. Also, it is engaged in the manufacturing of stainless steel exhaust systems, gauges, throttle controls, and trim tabs for the recreational marine industry. The company's operating segment includes Security Products and Marine Components. The company generates maximum revenue from the Security Products segment, which manufactures mechanical and electrical cabinet locks and other locking mechanisms. Its geographical segments are the United States, Canada, Mexico, and others, of which the United States accounts for the vast majority of revenue.

Share on Social Networks: